RxDoctor Payments Data

Krishna Chilukuri, MD

Family Medicine · Newburgh, INNPI 1841273968

Payments from drug & device makers

$1,167in general payments, 2019–2025

Across 16 payments — averaging $72.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$441
  • E.r. Squibb & Sons, L.L.C.$128
  • Travere Therapeutics, Inc.$125
  • Teva Pharmaceuticals USA, Inc.$123
  • Novo Nordisk$119
  • Bayer$115
  • plus $117 from 3 others

What the payments were for

  • Food & beverage$1,167100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,167 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$81,171
Medicare patients
255
Services billed
838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$77,012
OzempicSemaglutide35$54,025
JardianceEmpagliflozin49$34,907
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$21,983
MounjaroTirzepatide14$14,207
MyrbetriqMirabegron13$8,420
Rosuvastatin Calcium387$4,149
SynthroidLevothyroxine Sodium53$4,069
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,416
Amlodipine Besylate504$2,273
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$2,041
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide214$1,948
Pantoprazole Sodium169$1,903
Metoprolol Succinate199$1,885
Atorvastatin Calcium307$1,853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$119$54,02535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →